(Q44168595)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

title

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

author name string

Bo Gronlund

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

Heine H Hansen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

Svend A Engelholm

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

language of work or name

English

0 references

publication date

1 October 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

page(s)

1656-1662

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12365013%20AND%20SRC:MED&resulttype=core&format=json

Advances in ovarian cancer chemotherapy

13 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10838